08:00 , Dec 18, 2006 |  BC Week In Review  |  Clinical News

MG98: Development discontinued

MYG said following a strategic review of its cancer pipeline, it and partner MOGN will no longer pursue MG98 and will seek alternative development partners or arrangements for the compound. MG98 has completed the first...
07:00 , May 23, 2005 |  BC Week In Review  |  Clinical News

MG98: Phase I data

Data from a dose-escalation, Phase I trial of MG98 in 34 patients with advanced solid tumors showed that MG98 possessed antitumor activity and provided sustained reduction in DNA methyltransferase 1 (DNMT 1) expression. Patients received...
07:00 , May 23, 2005 |  BC Week In Review  |  Clinical News

MG98: Phase II data

Data from the Phase II Step 1 trial of MG98 in combination with interferon alpha to treat renal cell cancer showed that 1 patient on the continuous infusion schedule experienced a confirmed partial response by...
07:00 , Oct 11, 2004 |  BC Week In Review  |  Clinical News

MG98: Phase II start

MYG began a 2-step Phase II trial of MG98 plus interferon alpha. The first step will evaluate the safety, pharmacokinetics and optimal dosing of the combination therapy in 30-50 chemotherapy-naive patients. The second step will...
07:00 , Oct 6, 2004 |  BC Extra  |  Clinical News

MethylGene starts MG98 Phase II

MethylGene (TSE:MYG) began a two-step Phase II trial of its MG98 plus interferon alpha in patients with metastatic renal cell cancer. The first portion of the trial will evaluate safety, pharmacokinetics and optimal dosing of...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

MethylGene other research news

In vitro, MG98 sensitized renal cancer cells to interferon-induced apoptosis. Data were presented at the Molecular Targets and Cancer Therapeutics meeting in Boston. The compound is partnered in North America with MGI Pharma Inc....
07:00 , Apr 7, 2003 |  BC Week In Review  |  Clinical News

MG98: Phase I

In a Canadian Phase I trial, MG98 was well tolerated and caused objective tumor response or disease stabilization. MG98 is in U.S. and EU Phase I testing in solid and hematological tumors. MOGN has rights...
07:00 , Jul 15, 2002 |  BC Week In Review  |  Clinical News

MG98: Phase II

In a North American Phase II study, twice-weekly MG98 failed to give an objective clinical response in SCCHN patients. British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K.   MethylGene Inc., Montreal, Quebec   MGI Pharma Inc. (MOGN), Minneapolis,...
07:00 , Jul 15, 2002 |  BC Week In Review  |  Clinical News

MG98: Phase II

In a North American Phase II trial, twice-weekly MG98 failed to give an objective clinical response in RCC patients. BBG has European rights to MG98 under a February deal with MethylGene. MOGN has U.S. rights...
07:00 , Jul 15, 2002 |  BC Week In Review  |  Clinical News

MG98: BBG plans to start next quarter a Phase I study of a continuous infusion of MG98 over 2 weeks to treat solid tumors in an undisclosed number of patients.

British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K.   MethylGene Inc., Montreal, Quebec   MGI Pharma Inc. (MOGN), Minneapolis, Minn.   Business: Cancer   Product: MG98   Therapeutic category: Antisense   Description: Second generation antisense oligonucleotide targeting DNA methyltransferase   Target: ...